Edmonton, May 28-30, 2023

Due to the numerous requests from LPs. Micro and Craft growers along with some of the largest cannabis retail stores in the nation, Grow Up has decided to bring our award winning show to Alberta. We will be hosting our 7th Conference and Expo at the Edmonton Convention Centre in beautiful downtown Edmonton.

US DEA Facing Fresh Lawsuits After Denying Psilocybin Waiver, Rescheduling Request

Nov 1, 2022 | Media Partners, Psychedelic News Wire

This post is presented by our media partner Psychedelic News Wire
View the original article here.

For more than a year, a palliative care specialist has been fighting to be granted permission by the U.S. Drug Enforcement Administration (DEA) to administer psilocybin to his patients. Dr. Sunil Aggarwal had requested a federal waiver under the Right to Try statute, which would have allowed him to administer the psychedelic to his patients with terminal illnesses.

Aggarwal explained that Right to Try laws clearly stipulate that severely ill individuals qualified for investigational drugs, including psychedelics. However, the DEA rejected the request as well as a petition the doctor filed to reschedule psilocybin. In its argument, the federal agency states that this particular statute only discusses exemptions under the Federal Food, Drug and Cosmetic Act, which means that it does not have implications for the Controlled Substances Act.

The latest denial was announced in a letter, with the DEA stating that the FDA had not permitted the use of psilocybin as a medicine, which meant that it was still classified as a Schedule I substance under the Controlled Substances Act. This rejection letter doesn’t address the main point of Aggarwal’s petition, however, which is that the FDA has awarded breakthrough therapy designation to psilocybin for its use in treating severe depression. Last week, the physician’s attorneys challenged this rejection by the federal agency in the U.S. Court of Appeals for the Ninth Circuit. Opening briefs are due from the petitioners and the respondents on Jan. 9, 2023, and Feb. 7, 2023, respectively.

Aggarwal and his counsel have also submitted requests for various documents under the Freedom of Information Act in a bid to better understand the administrative process of the Drug Enforcement Administration. They have, in the past, accused the federal agency of purposely delaying the processing of these requests.

In addition to the ongoing litigation, the DEA is facing increased pressure from bipartisan legislators who filed measures in the Senate and House earlier this year to reaffirm that the scope of the Right to Try statute should include drugs classified under Schedule I.

The bill would make an amendment to the text of the current statute, with the primary objective being to clarify that the statute allows terminally ill patients to use investigational drugs even if they are controlled substances, as long as they have undergone clinical trials.

These companion measures were filed roughly six months after bipartisan legislators penned a letter to the DEA requesting that patients with terminal illnesses be permitted to use psilocybin as an investigational therapy without any legal repercussions.

Psychedelics companies such as Atai Life Sciences N.V. (NASDAQ: ATAI) are likely to watch closely as pioneering doctors such as Aggarwal battle to help terminally ill patients despite the DEA dragging its feet on the matter.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

This post was originally published by our media partner here.